Table 1 Baseline Characteristics of Patients

From: Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial

Feature

No.(%)

Age(years)

 ≥60

6(20.0)

 <60

24(80.0)

Gender

 Male

26(86.7)

 Female

4(13.3)

Etiology

 HBV

29(96.7)

 HCV

1(3.3)

ECOG Performance status

 0

29(96.7)

 1

1(3.3)

Child-Pugh

 A

28(93.3)

 B

2(6.7)

Tumor Numbers

 1

26(86.7)

 2

2(6.7)

 3

1(3.3)

 4

1(3.3)

Tumor Size(cm)#

 ≤5

4(13.3)

 >5 and ≤10

13(43.3)

 >10

13(43.3)

Macrovascular Invasion*

 2

7(23.3)

 3

8(26.7)

 4

15(50)

AFP(μg/L)

 <400

14(46.7)

 ≥400

16(53.3)

  1. HBV hepatitis B virus, HCV hepatitis C virus, ECOG eastern cooperative oncology group, AFP alpha-fetoprotein.
  2. #Tumor size was presented as the sum of longest diameters of the tumors.
  3. *MVI grade was modified based on the MVI grading system by the Liver Cancer Study Group of Japan; patients with Vp1, Vp2 or Vp3/Vv1 were classified as grade 1, 2 or 3 MVI, respectively; patients with Vp4, Vv2, Vv3, or both portal (Vp1–4) and hepatic vein invasion (Vv1–3) were classified as grade 4 MVI; Vp portal vein invasion, Vv hepatic vein invasion.
Back to article page